Monte Rosa Therapeutics/GLUE

$4.15

3.75%
-
1D1W1MYTD1YMAX

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Ticker

GLUE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Markus Warmuth

Employees

133

Headquarters

Boston, United States

GLUE Metrics

BasicAdvanced
$254M
Market cap
-
P/E ratio
-$2.53
EPS
-
Beta
-
Dividend rate
$254M
$8.84
$2.44
171K
4.82
-46.99%
-68.28%
-52.64%
239.01
1.376
1.667
-3.97%

What the Analysts think about GLUE

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 6 analysts.
285.54% upside
High $20.00
Low $11.00
$4.15
Current price
$16.00
Average price target

GLUE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,190% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
∞%
Net income
-$32M
-3.92%
Profit margin
-3,190%
-∞%

GLUE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.48%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.71
-$0.70
-$0.58
-$0.53
-
Expected
-$0.70
-$0.72
-$0.33
-$0.57
-$0.54
Surprise
1.43%
-3.28%
73.28%
-7.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Monte Rosa Therapeutics stock?

Monte Rosa Therapeutics (GLUE) has a market cap of $254M as of May 30, 2024.

What is the P/E ratio for Monte Rosa Therapeutics stock?

The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 0 as of May 30, 2024.

Does Monte Rosa Therapeutics stock pay dividends?

No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Monte Rosa Therapeutics dividend payment date?

Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.

What is the beta indicator for Monte Rosa Therapeutics?

Monte Rosa Therapeutics (GLUE) does not currently have a Beta indicator.

What is the Monte Rosa Therapeutics stock price target?

The target price for Monte Rosa Therapeutics (GLUE) stock is $16, which is 275.59% above the current price of $4.26. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Monte Rosa Therapeutics stock

Buy or sell Monte Rosa Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing